Skip to main content
Log in

An Extension of Janmahasatian’s Fat-Free Mass Model for Universal Application Across Populations of Different Ethnicities

  • Original Research Article
  • Published:
Clinical Pharmacokinetics Aims and scope Submit manuscript

A Letter to the Editor to this article was published on 22 May 2020

A Letter to the Editor to this article was published on 22 May 2020

Abstract

Background

Fat-free mass (FFM)-based dose scaling is increasingly being adopted in clinical pharmacology. Given the complexities with the measurement of FFM in clinical practice, choosing an appropriate equation for FFM is critical for accurate dose scaling. Janmahasatian’s FFM model (FFMJan) has largely remained the preferred choice because of its mechanistic basis and good predictive properties. This model was, however, developed from a largely European cohort and has been shown to give biased predictions of FFM in Indian people.

Objective

The objective of this work was to derive an extended version of the FFMJan model (FFMExt) that accounts for the variation in body composition due to ethnicity, and to demonstrate its application by developing an extended FFM model in an Indian population (FFMExt,Ind).

Methods

The fundamental assumption of FFMJan model development was a linear relationship between bioimpedance and body mass index. In this extension to Janmahasatian’s work, this assumption was extended to allow for potential non-linear relationships. While the original ZJan model parameters were kept fixed, a set of body composition-related parameters \(\varPsi \{ \psi_{1} , \;\psi_{2} , \;\psi_{3} \}\) were incorporated, where \(\psi_{1}\) and \(\psi_{2}\) were the ethnicity factors to the intercept and the linear coefficient, respectively, and \(\psi_{3}\) a non-linear exponent. The model was then applied to data arising from a south Indian population and the \(\varPsi\) parameters were estimated by standard non-linear regression. The data were generated from a reference model for FFM for the Indian population, which was known to provide unbiased estimates for this population.

Results

The parameter estimates (%RSE) of the final FFMExt,Ind model were \(\psi_{1} = 0\) (fixed), \(\psi_{2} = 0.77\) (3.2%) for male patients, 0.70 (3.3%) for female patients, and \(\psi_{3} = 0.72\) (12.4%). The final model predictions were in good agreement with the reference model predictions.

Conclusions

An FFMExt model has been achieved by extending the original FFMJan model assumptions to account for inter-ethnic differences in body composition. The extended model can be applied to any ethnic population by estimating a set of body composition-related parameters \(\varPsi\). This can be performed using bioimpedance data without the need for formal FFM measurements.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Siri WE. Body composition from fluid spaces and density: analysis of methods. In: Josef Brozek AH, editor. Techniques for measuring body composition. Washington, DC: National Academy of Sciences-National Research Council; 1961. p. 223–44.

    Google Scholar 

  2. Sinha J, Duffull SB, Al-Sallami HS. A review of the methods and associated mathematical models used in the measurement of fat-free mass. Clin Pharmacokinet. 2018;57(7):781–95.

    Article  Google Scholar 

  3. Green B, Duffull SB. What is the best size descriptor to use for pharmacokinetic studies in the obese? Br J Clin Pharmacol. 2004;58(2):119–33.

    Article  Google Scholar 

  4. De Baerdemaeker LE, Mortier EP, Struys MM. Pharmacokinetics in obese patients. Contin Educ Anaesth Crit Care Pain. 2004;4(5):152–5.

    Article  Google Scholar 

  5. Han P, Duffull S, Kirkpatrick C, Green B. Dosing in obesity: a simple solution to a big problem. Clin Pharmacol Ther. 2007;82(5):505–8.

    Article  CAS  Google Scholar 

  6. Eleveld DJ, Proost JH, Absalom AR, Struys MM. Obesity and allometric scaling of pharmacokinetics. Clin Pharmacokinet. 2011;50(11):751–3.

    Article  CAS  Google Scholar 

  7. Leykin Y, Miotto L, Pellis T. Pharmacokinetic considerations in the obese. Best Pract Res Clin Anaesthesiol. 2011;25(1):27–36.

    Article  CAS  Google Scholar 

  8. De Baerdemaeker LEC, Van Limmen JGM, Van Nieuwenhove Y. How should obesity be measured and how should anesthetic drug dosage be calculated? In: Leykin Y, Brodsky JB, editors. Controversies in the anesthetic management of the obese surgical patient. Milan: Springer; 2013. p. 15–30.

    Chapter  Google Scholar 

  9. Ingrande J, Brodsky JB, Lemmens HJ. Lean body weight scalar for the anesthetic induction dose of propofol in morbidly obese subjects. Anesth Analg. 2011;113(1):57–62.

    Article  CAS  Google Scholar 

  10. Cortinez LI, Anderson BJ, Holford NH, Puga V, de la Fuente N, Auad H, et al. Dexmedetomidine pharmacokinetics in the obese. Eur J Clin Pharmacol. 2015;71(12):1501–8.

    Article  CAS  Google Scholar 

  11. La Colla L, Albertin A, La Colla G, Porta A, Aldegheri G, Di Candia D, et al. Predictive performance of the ‘Minto’remifentanil pharmacokinetic parameter set in morbidly obese patients ensuing from a new method for calculating lean body mass. Clin Pharmacokinet. 2010;49(2):131–9.

    Article  Google Scholar 

  12. Janmahasatian S, Duffull SB, Ash S, Ward LC, Byrne NM, Green B. Quantification of lean bodyweight. Clin Pharmacokinet. 2005;44(10):1051–65.

    Article  Google Scholar 

  13. Al-Sallami HS, Goulding A, Grant A, Taylor R, Holford N, Duffull SB. Prediction of fat-free mass in children. Clin Pharmacokinet. 2015;54(11):1169–78.

    Article  CAS  Google Scholar 

  14. Rush EC, Plank LD, Laulu MS, Robinson SM. Prediction of percentage body fat from anthropometric measurements: comparison of New Zealand European and Polynesian young women. Am J Clin Nutr. 1997;66(1):2–7.

    Article  CAS  Google Scholar 

  15. Rush E, Plank L, Chandu V, Laulu M, Simmons D, Swinburn B, et al. Body size, body composition, and fat distribution: a comparison of young New Zealand men of European, Pacific Island, and Asian Indian ethnicities. N Z Med J. 2004;117(1207):U1203.

    PubMed  Google Scholar 

  16. Rush EC, Freitas I, Plank LD. Body size, body composition and fat distribution: comparative analysis of European, Maori, Pacific Island and Asian Indian adults. Br J Nutr. 2009;102(4):632–41.

    Article  CAS  Google Scholar 

  17. Swinburn B, Ley S, Carmichael H, Plank L. Body size and composition in Polynesians. Int J Obes. 1999;23(11):1178.

    Article  CAS  Google Scholar 

  18. Deurenberg P, Deurenberg-Yap M, Guricci S. Asians are different from Caucasians and from each other in their body mass index/body fat per cent relationship. Obes Rev. 2002;3(3):141–6.

    Article  CAS  Google Scholar 

  19. Srigiripura CV, Urooj A, Krishnarao CS, Anand MP. Validation of fat-free mass estimation using prediction equations in male patients with chronic obstructive pulmonary disease. Int J Nutr Pharmacol Neurol Dis. 2017;7(4):94–100.

    Article  Google Scholar 

  20. Kulkarni B, Kuper H, Taylor A, Wells JC, Radhakrishna KV, Kinra S, et al. Development and validation of anthropometric prediction equations for estimation of lean body mass and appendicular lean soft tissue in Indian men and women. J Appl Physiol. 2013;115(8):1156–62.

    Article  Google Scholar 

  21. McLeay S, Morrish G, Ponnuswamy T, Devanand B, Ramanathan M, Venkatakrishnan L, et al. Noninvasive quantification of hepatic steatosis: relationship between obesity status and liver fat content. Open Obes J. 2014;6(1):16–24.

    Article  Google Scholar 

  22. Akaike H. A new look at the statistical model identification. IEEE Trans Autom Control. 1974;19(6):716–23.

    Article  Google Scholar 

Download references

Acknowledgements

The authors acknowledge the contribution of T. K. Ponnuswamy, B. Devanand, M. Ramanathan, S. Ramalingam and Bruce Green for collecting and sharing the demographic data of 100 adult Indian patients for this analysis. During the conduct of the study, T. K. Ponnuswamy, B. Devanand and S. Ramalingam were from the PSG Institute of Medical Sciences and Research, Coimbatore, India; M. Ramanathan was from the PSG College of Pharmacy, Coimbatore, India and Bruce Green was from Model Answers R&D Pty Ltd, Brisbane, QLD, Australia.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Stephen B. Duffull.

Ethics declarations

Funding

This work required no specific funding. Jaydeep Sinha received a doctoral scholarship from the School of Pharmacy, University of Otago, New Zealand during this work.

Conflict of interest

Jaydeep Sinha, Hesham S. Al-Sallami and Stephen B. Duffull have no conflicts of interest that are directly relevant to the content of this article.

Ethics approval

No ethical approval was required for this analysis.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (DOCX 15 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sinha, J., Al-Sallami, H.S. & Duffull, S.B. An Extension of Janmahasatian’s Fat-Free Mass Model for Universal Application Across Populations of Different Ethnicities. Clin Pharmacokinet 59, 1161–1170 (2020). https://doi.org/10.1007/s40262-020-00883-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40262-020-00883-1

Navigation